FDA issues Guidance on Container Closure Systems (CCS) for Human Drugs

The USFDA has released a new draft guidance, Container Closure Systems for Human Drugs and Biological Products, outlining principles for evaluating CCSs for drugs and biological products. It provides a risk‑based framework for assessing packaging materials and components, and also detail quality assessment and control requirements. It provides recommendations regarding pharmaceutical quality considerations (Chemistry, Manufacturing and Controls (CMC)) for CCS for both drug products and drug substances

The guidance covers primary and secondary packaging components where the latter provide additional protection and aligns with the multitude of FD&C Act provisions, compendial requirements (USP‑NF) and references relevant 21 CFR and ICH guidelines. As per the FD&C Acts, drugs failing CCS requirements may be deemed adulterated or misbranded. FDA intends to supplement the guidance with additional topic specific guidance which will address the general requirements described in this guidance.

Risk assessment and Risk based framework:

The guidance presents a risk‑based approach to assessing container closure systems (CCS) and require firms to evaluate CCS suitability for each specific product. The Risk management process should address Material of Construction (MOC) of the CCS, Drug Manufacturing Process and the Drug’s Clinical Use with emphasis on interactions between drugs and packaging materials and mitigation strategies

The risk management process shall address risk factors including:

·        Safety of Packaging Material: Potential for harmful leachables from packing material, interaction of packing material with drug product and components, drug substance.

·        Protection of drug product / drug substance: Protection from ingress of external contaminants and external factors like light, loss of solvents, physical stress, exposure to reactive gases (like oxygen), humidity, microbial contaminants.

·        Performance: Ability of the drug product CCS to function as designed; for e.g, elastomeric closures on a multidose product should ensure closure / sealing after each use; A Metered Dose Inhaler (MDI) should deliver intended quantity of drug.

·        Impacts of Manufacturing Process: The risk assessment should evaluate potential effects of manufacturing process on the CCS (for example sterilisation, lyophilisation, washing and so on) and compatibility of the CCS to such treatments.

·        Storage and Handling: Assess whether CCS can maintain integrity and functional performance under intended products storage and handling conditions (For example freeze storage or refrigerated storage)

The guidance provides a useful matrix of examples of packaging concerns risk assessment based on Route of Administration (ROA) and Likelihood of interaction between packaging components and the drug product. It discusses common dosage forms like Inhalation products, Intranasal products, Injectables, Topical dermal products, Opthalmic and OTIC products, Oral drug products. ROA has four degrees of concern – Highest, High, Medium, Low and likelihood of interaction has three degrees of concern – High, Medium, Low and the matrix gives 12 risk levels from Highest – High (Inhalation products) to Low -Low for Oral products,

Quality Assessment and Control

The guidance also lays out expectations for quality control and stability testing. For drug products requirements as per 21 CFR PART 211 SUBPART E must be met and for drug substances quality control program should be implemented as per ICH Q7.  Adequate procedures for quality evaluation of the CCS including Tests and Assessments, Specifications for routine quality control, validations should be established.

The guidance provides a practical matrix of the Quality Characteristics to be considered for the CCS (Description, Protection, Compatibility & Safety, Performance, Quality control, Stability) vs the Dosage Form. The Quality Characteristic of Protection for example should consider factors such as reactive gases, moisture permeation, container closure integrity, solvent loss, leakage and Compatibility should consider factors like chemical composition, physicochemical tests, extractables and leachables and appropriate references to indirect food additive regulations.

CCS evaluation should be part of stability testing and for sterile products Container Closure Integrity Testing (CCIT) in lieu of sterility testing should be considered. The guidance also provides a useful list of CCIT tests for common type of CCS such as Vials, Bottles, Ampoules, Tubes, Blisters, Sachets and Pouches among others. The tests include Helium leak tests, Pressure or vacuum decay, Mass Extraction, Bubble emission, Dye Ingress, Burst / creep tests). To ensure Safety and compatibility CCS and packaging components and MOC should be well characterised with complete chemical composition of every material and adequate test results of the qualification and characterisation tests should be provided if the drug product is likely to interact with the CCS. For drugs that are unlikely to interact with CCS, appropriate reference to indirect food additive regulations can be made. Leachables studies should be performed through shelf life of the drug product as part of formal stability studies under both long-term and accelerated conditions.

A robust Quality control program should be established including Supplier Qualification program, sufficient initial tests and assessments and periodic assessments, component specifications

Additional Shipping studies to evaluate the integrity of CCS such as mechanical protective function of the CCS for environmental stress and physical stress during shipping should be performed. For drugs shipped under cold chain conditions qualification using temperature recording systems, freeze-thaw studies and thermal cycling studies should be considered.

The guidance also describes tests and studies for the secondary packaging components. If secondary packaging have an additional protective function, appropriate assessments to demonstrate the additional protection functions should be performed. If the primary CCS is relatively permeable migration of components from secondary packing is a potential source of contamination (adhesive, ink) and safety of the CCS should be assessed. For device constituent part of combination products, the device constituent part and combination product as a whole must be designed and tested to demonstrate device’s function and delivery performance (for example Prefilled syringes, MDIs)

Bulk Containers:  For bulk drug products  bulk containers should meet same requirements for protection, safety and compatibility as for the drug product CCS. For bulk containers for drug substances quality assessment should include detailed description of the CCS components, composition of each component, specifications for testing and release of the components and the analytical test methods.

In summary, the guidance provides a structured framework for evaluating and controlling Container Closure Systems (CCS). It emphasizes risk‑based assessment, robust quality control, and regulatory compliance to ensure packaging systems safeguard drug integrity throughout the product lifecycle.

Reference:

USFDA Guidance: Container Closure Systems for Human Drugs and Biological Products (Draft, August 2026)